B cell transcription factors: Potential new therapeutic targets for SLE

Clinical Immunology

Volumn 152, Issue 1-2, 2014, Pages 140-151

  De, Saurav ^a,b   Barnes, Betsy J ^a,b  

^a University of Medicine and Dentistry of New Jersey   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Autoimmunity; B cells; SLE; Transcription factors

Indexed keywords

B CELL ACTIVATING FACTOR; B CELL MATURATION ANTIGEN; B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; B LYMPHOCYTE RECEPTOR; CD40 LIGAND; I KAPPA B ALPHA; I KAPPA B BETA; IKAROS TRANSCRIPTION FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN MU CHAIN; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; INTERFERON REGULATORY FACTOR 5; INTERLEUKIN 7; RAG1 PROTEIN; RAG2 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E BOX; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR PU 1; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; APOPTOSIS; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; DENDRITIC CELL; DISEASE COURSE; DNA BINDING; ENZYME ACTIVATION; HUMAN; MACROPHAGE; MEMORY CELL; NATURAL KILLER CELL; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; VDJ RECOMBINATION;

AUTOIMMUNITY; B CELLS; SLE; TRANSCRIPTION FACTORS;

AUTOANTIBODIES; AUTOIMMUNITY; B-LYMPHOCYTES; HUMANS; IMMUNE TOLERANCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; TRANSCRIPTION FACTORS;

EID: 84897929868     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2014.03.009     Document Type: Review

References (105)

1. Tsokos G.C. Systemic lupus erythematosus. N. Engl. J. Med. 2011, 365(22):2110-2121.
2. D'Cruz D.P., Khamashta M.A., Hughes G.R. Systemic lupus erythematosus. Lancet 2007, 369(9561):587-596.
3. JF Merola B.B., Lu B., Karlson E.W., Massarotti E., Schur P.H., Costenbader K.H. Clinical manifestations and survival among adults with (SLE) according to age at diagnosis. Lupus 2014, (Electronic publication ahead of print). 10.1177/0961203314526291.
4. Heinlen L.D., et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum. 2007, 56(7):2344-2351.
5. Hardy R.R., Hayakawa K. B cell development pathways. Annu. Rev. Immunol. 2001, 19:595-621.
6. Ramirez J., Lukin K., Hagman J. From hematopoietic progenitors to B cells: mechanisms of lineage restriction and commitment. Curr. Opin. Immunol. 2010, 22(2):177-184.
7. Hagman J., Lukin K. Transcription factors drive B cell development. Curr. Opin. Immunol. 2006, 18(2):127-134.
8. Matthias P., Rolink A.G. Transcriptional networks in developing and mature B cells. Nat. Rev. Immunol. 2005, 5(6):497-508.
9. LeBien T.W. Fates of human B-cell precursors. Blood 2000, 96(1):9-23.
10. Kikuchi K., et al. IL-7 receptor signaling is necessary for stage transition in adult B cell development through up-regulation of EBF. J. Exp. Med. 2005, 201(8):1197-1203.
11. Herzog S., Reth M., Jumaa H. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat. Rev. Immunol. 2009, 9(3):195-205.
12. Cambier J.C., et al. B-cell anergy: from transgenic models to naturally occurring anergic B cells?. Nat. Rev. Immunol. 2007, 7(8):633-643.
13. Batten M., et al. BAFF mediates survival of peripheral immature B lymphocytes. J. Exp. Med. 2000, 192(10):1453-1466.
14. Scholz J.L., et al. The role of B lymphocyte stimulator in B cell biology: implications for the treatment of lupus. Lupus 2013, 22(4):350-360.
15. Pillai S., Cariappa A. The follicular versus marginal zone B lymphocyte cell fate decision. Nat. Rev. Immunol. 2009, 9(11):767-777.
16. Schiemann B., et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001, 293(5537):2111-2114.
17. Schneider P., et al. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J. Exp. Med. 2001, 194(11):1691-1697.
18. Harwood N.E., Batista F.D. Early events in B cell activation. Annu. Rev. Immunol. 2010, 28:185-210.
19. Shlomchik M.J., Weisel F. Germinal center selection and the development of memory B and plasma cells. Immunol. Rev. 2012, 247(1):52-63.
20. Yoshida T., et al. Memory B and memory plasma cells. Immunol. Rev. 2010, 237(1):117-139.
21. Cerutti A., Cols M., Puga I. Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat. Rev. Immunol. 2013, 13(2):118-132.
22. Sims G.P., et al. Identification and characterization of circulating human transitional B cells. Blood 2005, 105(11):4390-4398.
23. Dorner T., et al. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J. Immunol. Methods 2011, 363(2):187-197.
24. Eilertsen G.O., et al. Increased levels of BAFF in patients with systemic lupus erythematosus are associated with acute-phase reactants, independent of BAFF genetics: a case-control study. Rheumatology (Oxford) 2011, 50(12):2197-2205.
25. Mackay F., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med. 1999, 190(11):1697-1710.
26. Liu Z., Davidson A. BAFF and selection of autoreactive B cells. Trends Immunol. 2011, 32(8):388-394.
27. + memory B cell development. J. Exp. Med. 2006, 203(2):393-400.
28. Mizoguchi A., et al. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002, 16(2):219-230.
29. Fillatreau S., et al. B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 2002, 3(10):944-950.
30. Mauri C., Bosma A. Immune regulatory function of B cells. Annu. Rev. Immunol. 2012, 30:221-241.
31. Blair P.A., et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010, 32(1):129-140.
32. Chang N.H., et al. Expanded population of activated antigen-engaged cells within the naive B cell compartment of patients with systemic lupus erythematosus. J. Immunol. 2008, 180(2):1276-1284.
33. Yurasov S., et al. Persistent expression of autoantibodies in SLE patients in remission. J. Exp. Med. 2006, 203(10):2255-2261.
34. Odendahl M., et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 2000, 165(10):5970-5979.
35. Mackay M., et al. Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J. Exp. Med. 2006, 203(9):2157-2164.
36. Jacobi A.M., et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2003, 48(5):1332-1342.
37. Busslinger M. Transcriptional control of early B cell development. Annu. Rev. Immunol. 2004, 22:55-79.
38. Mandel E.M., Grosschedl R. Transcription control of early B cell differentiation. Curr. Opin. Immunol. 2010, 22(2):161-167.
39. McKercher S.R., et al. Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J. 1996, 15(20):5647-5658.
40. DeKoter R.P., Lee H.J., Singh H. PU.1 regulates expression of the interleukin-7 receptor in lymphoid progenitors. Immunity 2002, 16(2):297-309.
41. Kueh H.Y., et al. Positive feedback between PU.1 and the cell cycle controls myeloid differentiation. Science 2013, 341(6146):670-673.
42. Zhang X.K., et al. Decreased expression of the Ets family transcription factor Fli-1 markedly prolongs survival and significantly reduces renal disease in MRL/lpr mice. J. Immunol. 2004, 173(10):6481-6489.
43. Hikami K., et al. Association of a functional polymorphism in the 3'-untranslated region of SPI1 with systemic lupus erythematosus. Arthritis Rheum. 2011, 63(3):755-763.
44. Georgiou P., et al. Expression of ets family of genes in systemic lupus erythematosus and Sjogren's syndrome. Int. J. Oncol. 1996, 9(1):9-18.
45. Morris E.E., et al. A GA microsatellite in the Fli1 promoter modulates gene expression and is associated with systemic lupus erythematosus patients without nephritis. Arthritis Res. Ther. 2010, 12(6):R212.
46. Bradshaw S., et al. A role for Fli-1 in B cell proliferation: implications for SLE pathogenesis. Clin. Immunol. 2008, 129(1):19-30.
47. Bain G., et al. E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements. Cell 1994, 79(5):885-892.
48. Nutt S.L., Kee B.L. The transcriptional regulation of B cell lineage commitment. Immunity 2007, 26(6):715-725.
49. Herblot S., Aplan P.D., Hoang T. Gradient of E2A activity in B-cell development. Mol. Cell. Biol. 2002, 22(3):886-900.
50. Lin Y.C., et al. A global network of transcription factors, involving E2A, EBF1 and Foxo1, that orchestrates B cell fate. Nat. Immunol. 2010, 11(7):635-643.
51. O'Riordan M., Grosschedl R. Coordinate regulation of B cell differentiation by the transcription factors EBF and E2A. Immunity 1999, 11(1):21-31.
52. Gyory I., et al. Transcription factor Ebf1 regulates differentiation stage-specific signaling, proliferation, and survival of B cells. Genes Dev. 2012, 26(7):668-682.
53. Nordmark G., et al. Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjogren's syndrome. Genes Immun. 2011, 12(2):100-109.
54. Medvedovic J., et al. Pax5: a master regulator of B cell development and leukemogenesis. Adv. Immunol. 2011, 111:179-206.
55. Cobaleda C., et al. Pax5: the guardian of B cell identity and function. Nat. Immunol. 2007, 8(5):463-470.
56. Revilla I.D.R., et al. The B-cell identity factor Pax5 regulates distinct transcriptional programmes in early and late B lymphopoiesis. EMBO J. 2012, 31(14):3130-3146.
57. Nera K.P., et al. Loss of Pax5 promotes plasma cell differentiation. Immunity 2006, 24(3):283-293.
58. Heizmann B., Kastner P., Chan S. Ikaros is absolutely required for pre-B cell differentiation by attenuating IL-7 signals. J. Exp. Med. 2013, 210(13):2823-2832.
59. Sellars M., Kastner P., Chan S. Ikaros in B cell development and function. World J. Biol. Chem. 2011, 2(6):132-139.
60. Reynaud D., et al. Regulation of B cell fate commitment and immunoglobulin heavy-chain gene rearrangements by Ikaros. Nat. Immunol. 2008, 9(8):927-936.
61. Kirstetter P., et al. Ikaros is critical for B cell differentiation and function. Eur. J. Immunol. 2002, 32(3):720-730.
62. Ferreiros-Vidal I., et al. Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B-cell differentiation. Blood 2013, 121(10):1769-1782.
63. Sun J., et al. Lack of the transcriptional coactivator OBF-1 prevents the development of systemic lupus erythematosus-like phenotypes in Aiolos mutant mice. J. Immunol. 2003, 170(4):1699-1706.
64. He C.F., et al. TNIP1, SLC15A4, ETS1, RasGRP3 and IKZF1 are associated with clinical features of systemic lupus erythematosus in a Chinese Han population. Lupus 2010, 19(10):1181-1186.
65. Cunninghame Graham D.S., et al. Association of NCF2, IKZF1, IRF8, IFIH1, and TYK2 with systemic lupus erythematosus. PLoS Genet. 2011, 7(10):e1002341.
66. Hu W., et al. Down-regulated expression of IKZF1 mRNA in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Rheumatol. Int. 2011, 31(6):819-822.
67. Lessard C.J., et al. Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am. J. Hum. Genet. 2012, 90(4):648-660.
68. Lu R., et al. IRF-4,8 orchestrate the pre-B-to-B transition in lymphocyte development. Genes Dev. 2003, 17(14):1703-1708.
69. Lu R. Interferon regulatory factor 4 and 8 in B-cell development. Trends Immunol. 2008, 29(10):487-492.
70. Cattoretti G., et al. Stages of germinal center transit are defined by B cell transcription factor coexpression and relative abundance. J. Immunol. 2006, 177(10):6930-6939.
71. Lee C.H., et al. Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein. J. Exp. Med. 2006, 203(1):63-72.
72. Klein U., et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat. Immunol. 2006, 7(7):773-782.
73. Ochiai K., et al. Transcriptional regulation of germinal center B and plasma cell fates by dynamical control of IRF4. Immunity 2013, 38(5):918-929.
74. Lien C., et al. Critical role of IRF-5 in regulation of B-cell differentiation. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(10):4664-4668.
75. Fang C.M., et al. Unique contribution of IRF-5-Ikaros axis to the B-cell IgG2a response. Genes Immun. 2012, 13(5):421-430.
76. Savitsky D.A., et al. Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(22):10154-10159.
77. Feng D., et al. Irf5-deficient mice are protected from pristane-induced lupus via increased Th2 cytokines and altered IgG class switching. Eur. J. Immunol. 2012, 42(6):1477-1487.
78. -/- mice complicates interpretation of type I interferon production and antibody responses. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(15):E898-E904.
79. Lech M., et al. IRF4 deficiency abrogates lupus nephritis despite enhancing systemic cytokine production. J. Am. Soc. Nephrol. 2011, 22(8):1443-1452.
80. Biswas P.S., et al. Dual regulation of IRF4 function in T and B cells is required for the coordination of T-B cell interactions and the prevention of autoimmunity. J. Exp. Med. 2012, 209(3):581-596.
81. Chrabot B.S., et al. Genetic variation near IRF8 is associated with serologic and cytokine profiles in systemic lupus erythematosus and multiple sclerosis. Genes Immun. 2013, 14(8):471-478.
82. Pathak S., et al. A role for IRF8 in B cell anergy. J. Immunol. 2013, 191(12):6222-6230.
83. -/- mice have an intrinsic defect in their response to pristane-induced lupus. J. Immunol. 2012, 189(7):3741-3750.
84. Lofgren S.E., et al. Promoter insertion/deletion in the IRF5 gene is highly associated with susceptibility to systemic lupus erythematosus in distinct populations, but exerts a modest effect on gene expression in peripheral blood mononuclear cells. J. Rheumatol. 2010, 37(3):574-578.
85. Feng D., et al. Genetic variants and disease-associated factors contribute to enhanced interferon regulatory factor 5 expression in blood cells of patients with systemic lupus erythematosus. Arthritis Rheum. 2010, 62(2):562-573.
86. Niewold T.B., et al. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008, 58(8):2481-2487.
87. Graham R.R., et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(16):6758-6763.
88. Stone R.C., et al. RNA-Seq for enrichment and analysis of IRF5 transcript expression in SLE. PLoS One 2013, 8(1):e54487.
89. Kaileh M., Sen R. NF-kappaB function in B lymphocytes. Immunol. Rev. 2012, 246(1):254-271.
90. Goetz C.A., Baldwin A.S. NF-kappaB pathways in the immune system: control of the germinal center reaction. Immunol. Res. 2008, 41(3):233-247.
91. Pohl T., et al. The combined absence of NF-kappa B1 and c-Rel reveals that overlapping roles for these transcription factors in the B cell lineage are restricted to the activation and function of mature cells. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(7):4514-4519.
92. Cariappa A., et al. Nuclear factor kappa B is required for the development of marginal zone B lymphocytes. J. Exp. Med. 2000, 192(8):1175-1182.
93. Sasaki Y., et al. Canonical NF-kappaB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity 2006, 24(6):729-739.
94. Zarnegar B., et al. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(21):8108-8113.
95. Enzler T., et al. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 2006, 25(3):403-415.
96. Zhang W., et al. Aberrant CD40-induced NF-kappaB activation in human lupus B lymphocytes. PLoS One 2012, 7(8):e41644.
97. Lin Y., Wong K., Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science 1997, 276(5312):596-599.
98. Angelin-Duclos C., et al. Role of B-lymphocyte-induced maturation protein-1 in terminal differentiation of B cells and other cell lineages. Cold Spring Harb. Symp. Quant. Biol. 1999, 64:61-70.
99. Shapiro-Shelef M., et al. Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J. Exp. Med. 2005, 202(11):1471-1476.
100. Shaffer A.L., et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002, 17(1):51-62.
101. Todd D.J., et al. XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development. J. Exp. Med. 2009, 206(10):2151-2159.
102. Shaffer A.L., et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 2004, 21(1):81-93.
103. Luo J., et al. Up-regulation of transcription factor Blimp1 in systemic lupus erythematosus. Mol. Immunol. 2013, 56(4):574-582.
104. Zhou Z., et al. Blimp-1 siRNA inhibits B cell differentiation and prevents the development of lupus in mice. Hum. Immunol. 2013, 74(3):297-301.
105. Palanichamy A., et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J. Immunol. 2009, 182(10):5982-5993.